Altering the Natural History of Allergic Diseases With Immunotherapy (MOC)

You can earn up to 2.0 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 2.0 MOC Part II Self-Assessment credits. Cost: $40 $20 for College Members, $60 $30 for non-members.

These presentations will review: 1) the most current data on the use of SCIT and SLIT to treat respiratory allergies; 2) the current status of immunotherapy for the treatment of food allergy focusing on the risks and benefits of oral, sublingual and epicutaneous immunotherapy, novel forms of immunotherapy in the preclinical stage and their potential benefits over more conventional therapies; and 3) whether allergy practices should offer SLIT to their patients, examine why we offer SLIT in our practice, discuss how SLIT extract is mixed, how the allergist practices charge for the extract, and also pros and cons of SLIT.


Release Date: 12/15/2015
Expiration Date: 12/14/2018


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

• Recognize the similarities and differences in logistics, efficacy, and safety of SLIT and SCIT for inhalant allergies 
• Discuss results of recent food allergy immunotherapy clinical trials 
• Discuss likely future strategies for performing immunotherapy, including using adjuvants, biologicals, and peptides

Additional information
Myron J. Zitt, MD, FACAAI -- Consultant/Advisor: Integrity, Sanofi, McNeil, Boehringer Ingelheim; Speaker: Integrity, Mylan, Meda, Boston Scientific

Harold S. Nelson, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Circassia, Merck, Pearl Therapeutics; Supported/Contracted Research: Circassia

Stanley M. Fineman, MD, MBA, FACAAI -- Speaker: AstraZeneca, Genentech, Meda, Merck, Mylan; Supported/Contracted Research: Genentech, Meda

Kari C. Nadeau, MD, PhD -- No financial relationships to disclose

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Attendance
  • 2.00 MOC
Course opens: 
Course expires: 

Myron Zitt, MD, FACAAI

Harold S. Nelson, MD, FACAAI

Kari C. Nadeau, MD, PhD

Stanley M. Fineman, MD, MBA, FACAAI

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Attendance
  • 2.00 MOC


Please login or create an account to take this course.